Silence Therapeutics plc - Product Pipeline Review - H2 2011
Summary
Global Market Direct’s pharmaceuticals report, “Silence Therapeutics plc - Product Pipeline Review - H2 2011” provides data on the Silence Therapeutics plc’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Silence Therapeutics plc’s corporate website, SEC filings, investor presentations and featured press releases, both from Silence Therapeutics plc and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
Reasons to buy
Summary
Global Market Direct’s pharmaceuticals report, “Silence Therapeutics plc - Product Pipeline Review - H2 2011” provides data on the Silence Therapeutics plc’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Silence Therapeutics plc’s corporate website, SEC filings, investor presentations and featured press releases, both from Silence Therapeutics plc and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Silence Therapeutics plc - Brief Silence Therapeutics plc overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Silence Therapeutics plc human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Silence Therapeutics plc with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Silence Therapeutics plc’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Silence Therapeutics plc’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Silence Therapeutics plc in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Silence Therapeutics plc’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Silence Therapeutics plc.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Silence Therapeutics plc and identify potential opportunities in those areas.
Silence Therapeutics plc Snapshot
Silence Therapeutics plc Overview
Key Information
Key Facts
Silence Therapeutics plc – Research and Development Overview
Key Therapeutic Areas
Silence Therapeutics plc – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Silence Therapeutics plc – Pipeline Products Glance
Silence Therapeutics plc Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Silence Therapeutics plc – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Silence Therapeutics plc – Drug Profiles
Atu-027
Atu027
Atu111
Atu134
Atu150
Silence Therapeutics plc – Pipeline Analysis
Silence Therapeutics plc – Pipeline Products by Therapeutic Class
Silence Therapeutics plc - Pipeline Products By Target
Silence Therapeutics plc – Pipeline Products by Route of Administration
Silence Therapeutics plc – Pipeline Products by Molecule Type
Silence Therapeutics plc – Recent Pipeline Updates
Silence Therapeutics plc - Dormant Projects
Silence Therapeutics plc - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
SRP312
Silence Therapeutics plc – Locations And Subsidiaries
Head Office
Company's Recent Developments
Silence Therapeutics plc, Recent Developments
Mar 30, 2011: Silence Therapeutics’s Phase I Atu027 Data Accepted For Presentation At American Society Of Clinical Oncology 2011 Annual Meeting
Oct 24, 2011: Silence Therapeutics Collaborates With Mirna To Evaluate Delivery Of Novel MicroRNA Therapeutics
May 18, 2011: Silence Therapeutics To Present New Data From Phase I Study Of Atu027 At 2011 ASCO Annual Meeting
Nov 10, 2010: Silence Reports Positive Preclinical Research Findings Of Atu027 In Pulmonary Metastasis Animal Models
Nov 08, 2011: Silence Provides Development Update Of Atu134
Nov 08, 2011: Silence Provides Update On Phase I Trial Of Atu027 In Advanced Solid Cancer
Jun 06, 2011: Silence Therapeutics’s Atu027 Demonstrates Promising Antitumor Activity In Phase I Study Presented At ASCO
Financial Deals Landscape
Silence Therapeutics plc, Deals Summary
Silence Therapeutics plc, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Atugen Raises $6.16 Million In Financing
Partnerships
Silence Therapeutics Enters Into Co-Development Agreement With InteRNA Technologies
Silence Therapeutics Extends R&D Collaboration With AstraZeneca
Licensing Agreements
Quark Expands Licensing Agreement With Silence Therapeutics
Atugen Enters Into Licensing Agreement With Merck & Co.
Atugen Entends Licensing Agreement with Altana Pharma
Equity Offering
Silence Therapeutics Completes Private Placement Of $9 Million
Silence Therapeutics Completes Public Offering Of $0.71 Million
Acquisition
Silence Therapeutics To Sell Its Stake To A Drug Firm
Silence Therapeutics Completes Acquisition Of Intradigm
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Silence Therapeutics plc, Key Information
Silence Therapeutics plc, Key Facts
Silence Therapeutics plc – Pipeline by Therapy Area and Indication, H2 2011
Silence Therapeutics plc – Pipeline by Stage of Development, H2 2011
Silence Therapeutics plc – Monotherapy Products in Pipeline, H2 2011
Silence Therapeutics plc - Phase I, H2 2011
Silence Therapeutics plc – Pre-Clinical, H2 2011
Silence Therapeutics plc - Pipeline By Therapeutic Class, H2 2011
Silence Therapeutics plc - Pipeline By Target, H2 2011
Silence Therapeutics plc – Pipeline By Route of Administration, H2 2011
Silence Therapeutics plc – Pipeline By Molecule Type, H2 2011
Silence Therapeutics plc – Recent Pipeline Updates, H2 2011
Silence Therapeutics plc - Dormant Developmental Projects, 2010
Silence Therapeutics plc - Discontinued Pipeline Products, 2010
Silence Therapeutics plc, Deals Summary
Atugen Raises $6.16 Million In Financing
Silence Therapeutics Enters Into Co-Development Agreement With InteRNA Technologies
Silence Therapeutics Extends R&D Collaboration With AstraZeneca
Silence Therapeutics Extends Co-Development Agreement With AstraZeneca
Silence Therapeutics Expands Its Collaboration With Dainippon Sumitomo Pharma
Silence Therapeutics Enters Into Agreement With Dainippon Sumitomo Pharma
AstraZeneca Enters Into An Agreement With Silence Therapeutics
Silence Therapeutics Enters Into An Agreement With AstraZeneca
ASINEX Enters Into Co-Development Agreement With Atugen
Atugen Enters Into Research Agreement With Aventis
Quark Expands Licensing Agreement With Silence Therapeutics
Atugen Enters Into Licensing Agreement With Merck & Co.
Atugen Entends Licensing Agreement with Altana Pharma
Silence Therapeutics Completes Private Placement Of $9 Million
Silence Therapeutics Completes Public Offering Of $0.71 Million
Silence Therapeutics Completes Private Placement Of $24 Million
Silence Therapeutics Completes Private Placement Of $4.05 Million
Silence Therapeutics To Sell Its Stake To A Drug Firm
Silence Therapeutics Completes Acquisition Of Intradigm
SR Pharma Acquires Atugen
Introgen Therapeutics Acquires Stake In SR Pharma
LIST OF FIGURES
Silence Therapeutics plc – Pipeline by Therapy Area and Indication, H2 2011
Silence Therapeutics plc – Pipeline by Stage of Development, H2 2011
Silence Therapeutics plc – Monotherapy Products in Pipeline, H2 2011
Silence Therapeutics plc – Pipeline By Therapeutic Class, H2 2011
Silence Therapeutics plc - Pipeline By Target, H2 2011
Silence Therapeutics plc – Pipeline By Route of Administration, H2 2011
Silence Therapeutics plc – Pipeline By Molecule Type, H2 2011
Silence Therapeutics plc Overview
Key Information
Key Facts
Silence Therapeutics plc – Research and Development Overview
Key Therapeutic Areas
Silence Therapeutics plc – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Silence Therapeutics plc – Pipeline Products Glance
Silence Therapeutics plc Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Silence Therapeutics plc – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Silence Therapeutics plc – Drug Profiles
Atu-027
Atu027
Atu111
Atu134
Atu150
Silence Therapeutics plc – Pipeline Analysis
Silence Therapeutics plc – Pipeline Products by Therapeutic Class
Silence Therapeutics plc - Pipeline Products By Target
Silence Therapeutics plc – Pipeline Products by Route of Administration
Silence Therapeutics plc – Pipeline Products by Molecule Type
Silence Therapeutics plc – Recent Pipeline Updates
Silence Therapeutics plc - Dormant Projects
Silence Therapeutics plc - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
SRP312
Silence Therapeutics plc – Locations And Subsidiaries
Head Office
Company's Recent Developments
Silence Therapeutics plc, Recent Developments
Mar 30, 2011: Silence Therapeutics’s Phase I Atu027 Data Accepted For Presentation At American Society Of Clinical Oncology 2011 Annual Meeting
Oct 24, 2011: Silence Therapeutics Collaborates With Mirna To Evaluate Delivery Of Novel MicroRNA Therapeutics
May 18, 2011: Silence Therapeutics To Present New Data From Phase I Study Of Atu027 At 2011 ASCO Annual Meeting
Nov 10, 2010: Silence Reports Positive Preclinical Research Findings Of Atu027 In Pulmonary Metastasis Animal Models
Nov 08, 2011: Silence Provides Development Update Of Atu134
Nov 08, 2011: Silence Provides Update On Phase I Trial Of Atu027 In Advanced Solid Cancer
Jun 06, 2011: Silence Therapeutics’s Atu027 Demonstrates Promising Antitumor Activity In Phase I Study Presented At ASCO
Financial Deals Landscape
Silence Therapeutics plc, Deals Summary
Silence Therapeutics plc, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Atugen Raises $6.16 Million In Financing
Partnerships
Silence Therapeutics Enters Into Co-Development Agreement With InteRNA Technologies
Silence Therapeutics Extends R&D Collaboration With AstraZeneca
Licensing Agreements
Quark Expands Licensing Agreement With Silence Therapeutics
Atugen Enters Into Licensing Agreement With Merck & Co.
Atugen Entends Licensing Agreement with Altana Pharma
Equity Offering
Silence Therapeutics Completes Private Placement Of $9 Million
Silence Therapeutics Completes Public Offering Of $0.71 Million
Acquisition
Silence Therapeutics To Sell Its Stake To A Drug Firm
Silence Therapeutics Completes Acquisition Of Intradigm
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Silence Therapeutics plc, Key Information
Silence Therapeutics plc, Key Facts
Silence Therapeutics plc – Pipeline by Therapy Area and Indication, H2 2011
Silence Therapeutics plc – Pipeline by Stage of Development, H2 2011
Silence Therapeutics plc – Monotherapy Products in Pipeline, H2 2011
Silence Therapeutics plc - Phase I, H2 2011
Silence Therapeutics plc – Pre-Clinical, H2 2011
Silence Therapeutics plc - Pipeline By Therapeutic Class, H2 2011
Silence Therapeutics plc - Pipeline By Target, H2 2011
Silence Therapeutics plc – Pipeline By Route of Administration, H2 2011
Silence Therapeutics plc – Pipeline By Molecule Type, H2 2011
Silence Therapeutics plc – Recent Pipeline Updates, H2 2011
Silence Therapeutics plc - Dormant Developmental Projects, 2010
Silence Therapeutics plc - Discontinued Pipeline Products, 2010
Silence Therapeutics plc, Deals Summary
Atugen Raises $6.16 Million In Financing
Silence Therapeutics Enters Into Co-Development Agreement With InteRNA Technologies
Silence Therapeutics Extends R&D Collaboration With AstraZeneca
Silence Therapeutics Extends Co-Development Agreement With AstraZeneca
Silence Therapeutics Expands Its Collaboration With Dainippon Sumitomo Pharma
Silence Therapeutics Enters Into Agreement With Dainippon Sumitomo Pharma
AstraZeneca Enters Into An Agreement With Silence Therapeutics
Silence Therapeutics Enters Into An Agreement With AstraZeneca
ASINEX Enters Into Co-Development Agreement With Atugen
Atugen Enters Into Research Agreement With Aventis
Quark Expands Licensing Agreement With Silence Therapeutics
Atugen Enters Into Licensing Agreement With Merck & Co.
Atugen Entends Licensing Agreement with Altana Pharma
Silence Therapeutics Completes Private Placement Of $9 Million
Silence Therapeutics Completes Public Offering Of $0.71 Million
Silence Therapeutics Completes Private Placement Of $24 Million
Silence Therapeutics Completes Private Placement Of $4.05 Million
Silence Therapeutics To Sell Its Stake To A Drug Firm
Silence Therapeutics Completes Acquisition Of Intradigm
SR Pharma Acquires Atugen
Introgen Therapeutics Acquires Stake In SR Pharma
LIST OF FIGURES
Silence Therapeutics plc – Pipeline by Therapy Area and Indication, H2 2011
Silence Therapeutics plc – Pipeline by Stage of Development, H2 2011
Silence Therapeutics plc – Monotherapy Products in Pipeline, H2 2011
Silence Therapeutics plc – Pipeline By Therapeutic Class, H2 2011
Silence Therapeutics plc - Pipeline By Target, H2 2011
Silence Therapeutics plc – Pipeline By Route of Administration, H2 2011
Silence Therapeutics plc – Pipeline By Molecule Type, H2 2011